Abstract: Analogues of 8-D-homoarginine vasopressin were prepared with the general formula ##STR1## where X is L-O-methyltyrosine, L-p-ethylphenylalanine, D-p-ethylphenylalanine, L-p-methylphenylalanine or D-methylphenylalanine and R is cysteine or .beta.-mercaptopropionic acid. These vasopressin analogues exhibited an increased affinity to uterus receptors for oxytocin, where they acted as ocytocin antagonists. Moreover, the analogues of deamino vasopressin have a significantly reduced antidiuretic activity in comparison with [8-D-arginine]vasopressin.

Abstract: There is disclosed, in one aspect, an antidiuretic composition in oral dosage form for humans. This composition comprises an antidiuretically effective amount of 1-deamino-8-D-arginine vasopressin (DDAVP) and a pharmaceutically acceptable carrier. The composition is capable of dissolving and being absorbed in the gastrointestinal tract of a human. The composition isused in tablet, capsule, or other generally accepted oral dosage form and generally from about 50 to about 200 micrograms of DDAVP is used per unit dosage In another aspect, there is disclosed a method for treating diabetes insipidus. This method comprises orally administering an antidiuretically effective amount of DDAVP to a human. The DDAVP is substantially dissolved and absorbed in the gastrointestinal tract of the person so treated.

Abstract: The present invention provides a method and an apparatus for delivering medicinals to animal or human bladders. The apparatus is a polymeric, minicellular container surrounding an internal reservoir which contains the medicinal. The apparatus delivers the medicinal to the bladder at a prolonged, continuous and controlled rate.